Many cancer patients cannot benefit from cancer immunotherapy because their tumors are protected from the immune system. Neobe Therapeutics’ bacterial…
Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could usher in off-the-shelf cancer immunotherapies.…
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has signed a second clinical trial collaboration and supply agreement with…